MMP‐2 and MMP‐9 as prognostic markers for the early detection of urinary bladder cancer

• Published in: Journal of biochemical and molecular toxicology Vol. 33; no. 4; pp. e22275 - n/a
• Main Authors: Fouad, Hanan, Salem, Hosni, Ellakwa, Doha El‐Sayed, Abdel‐Hamid, Manal
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2019
• Subjects: Bladder; Bladder cancer; Blood; Gene expression; Matrix metalloproteinase; matrix metalloproteinase‐2; matrix metalloproteinase‐9; Metalloproteinase; Proteins; Sensitivity analysis; Tissue inhibitor of metalloproteinases; Tumors; Urinary bladder; Urine; western blot analysis; matrix metalloproteinase-2; western blot analysis; matrix metalloproteinase-9; bladder cancer
• ISSN: 1095-6670; 1099-0461; 1099-0461
• DOI: 10.1002/jbt.22275

The present study assessed protein and gene expression levels of tissue inhibitor of metalloproteinase‐2 (TIMP‐2), matrix metalloproteinase‐2 (MMP‐2), and MMP‐9 in urine and blood samples of 50 patients with bladder carcinoma. The expression of TIMP‐2, MMP‐2, and MMP‐9 levels with tumor stage and grade was also assessed. Results showed that the expression levels of MMP‐2 and MMP‐9 in both blood and urine were significantly elevated in group 1 when compared with groups 2 and 3 healthy subjects. The discriminatory ability in the diagnosis of bladder carcinoma of MMP‐2 and MMP‐9 expression was confirmed by receiver operating characteristic curve analysis that revealed a sensitivity and specificity of 100%. MMP‐2 and MMP‐9 levels were not correlated with grade or stage of the tumor. With respect to TIMP‐2 blood and urine levels, results showed a significant decrease in gene expression levels in bladder carcinoma group, whereas, TIMP‐2 protein showed a significant increase in bladder carcinoma.